Hansa Biopharma, a company involved in immunomodulatory enzyme technology for rare IgG mediated diseases, has named Professor Achim Kaufhold as its new chief medical officer, it was reported on Friday.

Kaufhold has served as CMO and member of the Executive Committee at Basilea Pharmaceutica in Switzerland. He is a senior pharmaceutical executive within immunology, infectious diseases and oncology.

Soren Tulstrup, president and CEO, Hansa Biopharma, said, 'I am very happy that we have managed to attract Achim Kaufhold as CMO. 2020 promises to be a transformative year for our company with the potential EU regulatory approval of imlifidase in kidney transplantation and top line data from the first phase 2 trial in autoimmune diseases.'